Glucagon has a noble history in the annals of metabolic disease, 1 even though, to a layperson, insulin is its more famous counterregulatory partner. For decades medical students have been taught that glucagon raises blood glucose by increasing hepatic glucose output and that alleviation of hypoglycaemia is its primary function. 2 Thus, inhibition of glucagon secretion 3 or action 4 are logical approaches to the development of therapeutics that improve glycaemic control in both type 2 and type 1 diabetes mellitus; indeed, this strategy has been pursued for nearly 4 decades.
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The situation, however, is complex. The preproglucagon gene product can be cleaved at various points by specific prohormone convertases to yield several bioactive peptides, including glucagon, in a tissue-selective manner. 1 Prohormone convertase 2 is expressed in pancreatic islets to generate mainly glucagon in α cells. By contrast, prohormone convertase 1/3 processes proglucagon in the gut and brain to glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), glicentin and oxyntomodulin. These boundaries are not absolute, however, and the relative abundance of these peptides in a tissue, and therefore its secretory potential, can vary depending on the differential expression of the processing enzymes. 5 There is evidence that GLP-1 is expressed in pancreatic islets, 6, 7 while glucagon may be secreted by enteroendocrine cells in the gut. 8 Enteroendocrine cells also express other peptides such as peptide-tyrosinetyrosine (PYY), 9, 10 and it now appears that secretion can be modulated by feedback inhibition by homotypic (GLP-1 reducing GLP-1 secretion) as well as heterotypic mechanisms (GLP-1 reducing PYY secretion).
11,12
Glucagon receptor pharmacology is also multifaceted. The classic glucagon receptor 13 is a member of the class B G-protein-coupled receptor (GPCR) family, 14 and its structure has been reported recently. 15, 16 In classic experiments, glucagon was shown to elevate intracellular G-protein-coupled adenylyl cyclase activity and increase cAMP levels 14 ; however, as with other GPCRs, the intracellular signal cascade can be modulated by other actions of G-proteins. In addition, the glucagon receptor can be desensitized after activation by internalization, and accessory proteins, such as β-arrestin and receptoractivity-modifying proteins (RAMPs), can modulate recycling of receptors to the cell surface. 17 To add complexity to this brew, not only can glucagon signal via the classic glucagon receptor, 14 but it can also interact with the "GLP-1" receptor with an affinity comparable to that of GLP-1 itself. 18, 19 Indeed, oxyntomodulin, essentially a glucagon molecule with a short C-terminal extension, can also signal both via the glucagon 20 and GLP-1 receptors. 21 Recently the oxyntomodulin-GLP-1 receptor interaction has been shown to exhibit biased agonism, 22 and this may also apply to glucagon-GLP-1 receptor signalling.
Thus, glucagon fits into a complex "systems biology" network of ligands and targets 23 (Table 1) have uncovered good, bad and ugly aspects in humans (Table 2) 25 ; therefore, the essential question for drug development is whether these features can be REGN1193 is a monoclonal antibody that blocks the glucagon receptor with a half maximal inhibitory concentration (IC 50 ) of ≈68 pM, as estimated from the inhibition of glucagon signalling in a cell-based reporter assay. This antibody binds with high affinity to mouse, rat, monkey and human glucagon receptors, allowing translation of pharmacodynamics across species. REGN1193 has been administered to diabetic and obese mice and diabetic monkeys 48 and data from these studies were used to select doses for evaluation in the present FTIH study. In this randomized, placebo-controlled FTIH study, REGN1193 was administered by intravenous (i.v.) infusion to healthy subjects as single doses ranging from 0.05 to 0.6 mg/kg. In addition to safety and pharmacokinetic measurements, the authors 26 increase circulating amino acid levels, resulting in pancreatic islet α-cell hyperplasia. 51, 52 tracked pharmacodynamics directly using the inhibition of the hyperglycaemic response to a standardized glucagon challenge (0.8 mg i.v.).
Onset-of-action was investigated using a pharmacologically active 0.3 mg/kg dose and the standardized glucagon stimulation test.
Development of anti-drug antibodies was monitored over the 15-week observation period.
REGN1193 exhibited markedly non-linear clearance, resulting in half-life estimates of 0.5 days for the 0.05 mg/kg dose to 4 days for the 0.6 mg/kg dose. Anti-drug antibody formation was unremarkable and did not contribute to the variable pharmacokinetics. The pharmacodynamic profile observed is summarized in Table 3 . As expected from the non-clinical data, the higher doses of REGN1193 blocked the elevation of plasma glucose and C-peptide seen with the glucagon challenge, effects consistent with the reported actions of the non-peptide small molecule antagonists and antisense molecules listed in Table 1 . The blocking effect of REGN1193 was evident as early as 6 h post-dose and persisted for at least 3 weeks. Previous work with the small molecule MK-0893 demonstrated predictable glucose-lowering in subjects with diabetes based on the degree of inhibition of glucagon-mediated hyperglycaemia 31 ; however, it is essential that the effects of REGN1193 be tested in subjects with type 2 diabetes to estimate clinical effects and allow comparison with the ≥1% glycated haemoglobin (HbA1c) reductions observed with the small molecule antagonists 31, 32, [34] [35] [36] 40, 54 and antisense molecules. 43 While the "good" appears to be very good in terms of HbA1c reduction, inhibition of glucagon signalling in humans appears to carry liabilities (Table 2) , and this has led to the termination of several drug development programmes in phase II or before (Table 1 ). It appears that all interventions in rodents that have interrupted glucagon receptor signalling have resulted in pancreatic islet α-cell (and δ-cell) hyperplasia to a greater or lesser extent 26, 49, 50, 55, 56 related to the degree of interruption of a liver signal. 57 Recently, a causal link has been established in glucagon receptor knockout mice between increased circulating amino acid levels, in particular glutamine, and the α-cell hyperplasia. 51, 52 In this context, it is interesting to note that administration of 75 mg/kg REGN1193 for 8 weeks to normoglycaemic cynomolgus monkeys did not increase pancreatic α-cell area, but did increase circulating amino acids, including glutamine; for comparison, 20 mg/kg was pharmacologically active in diabetic monkeys. 48 This may be evidence of a difference in responsivity between murine and monkey islets or insufficient "dose × time" or a combination of both, but it is notable that humans with loss-of-function glucagon receptor mutations demonstrate α-cell hypertrophy. [27] [28] [29] The data relating to reversible increases in ALT and AST (without elevation of bilirubin) appear to be consistent across all glucagon receptor blocking modalities and there is now a report that LY240921 increases liver fat measured by MRI. 37 As regards the elevation of LDL cholesterol initially observed with MK-0893 and MK-3577, 32 ,34 this appears to correlate with the magnitude of glucose-lowering in people with type 2 diabetes, suggesting a mechanism-based association, perhaps through altered absorption of cholesterol. 58 Initially, variable data were presented for LY240921 (no significant increase in LDL cholesterol after 12 or 24 weeks of treatment, 36 elevation of total cholesterol 54 ), but a more recent full publication clearly shows that 6 months of treatment with the compound increases circulating total cholesterol accompanied by a non-significant increase in LDL cholesterol compared with placebo. 37 This is consistent with results using a different molecule, PF-06291874, in which the highest dose 
